If you liked this article you might like

Surveying the NASH Drug Landscape
Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector
Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season
EQT Midstream Partners, AbbVie, Blackstone Group: 'Mad Money' Lightning Round